Elevance Health, Inc. (NYSE:ELV) Shares Bought by Capital Advisors Ltd. LLC

Capital Advisors Ltd. LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV) by 8.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 248 shares of the company’s stock after buying an additional 20 shares during the period. Capital Advisors Ltd. LLC’s holdings in Elevance Health were worth $129,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Sanders Capital LLC grew its holdings in shares of Elevance Health by 4.6% during the fourth quarter. Sanders Capital LLC now owns 4,457,986 shares of the company’s stock valued at $2,102,208,000 after purchasing an additional 196,010 shares during the last quarter. Capital International Investors grew its stake in Elevance Health by 7.9% during the 4th quarter. Capital International Investors now owns 3,374,709 shares of the company’s stock worth $1,591,237,000 after buying an additional 248,150 shares during the last quarter. Baillie Gifford & Co. increased its position in Elevance Health by 0.9% in the fourth quarter. Baillie Gifford & Co. now owns 3,087,904 shares of the company’s stock worth $1,456,132,000 after buying an additional 27,986 shares during the period. Norges Bank bought a new stake in Elevance Health in the fourth quarter valued at $1,347,434,000. Finally, Morgan Stanley boosted its holdings in shares of Elevance Health by 1.7% during the third quarter. Morgan Stanley now owns 2,784,714 shares of the company’s stock valued at $1,212,521,000 after acquiring an additional 46,322 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ELV shares. UBS Group lifted their price objective on shares of Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Jefferies Financial Group boosted their price objective on Elevance Health from $602.00 to $604.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Bank of America raised their target price on Elevance Health from $621.00 to $646.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Royal Bank of Canada boosted their price target on Elevance Health from $574.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, April 19th. Finally, Truist Financial reissued a “buy” rating and issued a $600.00 price target (up previously from $580.00) on shares of Elevance Health in a research note on Friday, April 19th. One analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $611.36.

Elevance Health Trading Up 0.3 %

NYSE ELV opened at $535.92 on Wednesday. The stock has a market cap of $124.56 billion, a price-to-earnings ratio of 20.25, a PEG ratio of 1.20 and a beta of 0.84. The firm’s 50 day moving average price is $534.41 and its two-hundred day moving average price is $509.38. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.37 and a current ratio of 1.37. Elevance Health, Inc. has a twelve month low of $412.00 and a twelve month high of $550.34.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Thursday, April 18th. The company reported $10.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.54 by $0.10. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The firm had revenue of $42.27 billion during the quarter, compared to the consensus estimate of $42.49 billion. During the same period in the prior year, the business earned $9.46 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. Equities analysts anticipate that Elevance Health, Inc. will post 37.25 EPS for the current year.

Elevance Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th were paid a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date was Monday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 24.64%.

Insider Activity

In other news, EVP Felicia F. Norwood sold 14,111 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total value of $7,531,605.14. Following the transaction, the executive vice president now directly owns 31,460 shares of the company’s stock, valued at $16,791,460.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.29% of the stock is currently owned by corporate insiders.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.